NCCN Guidelines Panel: Breast Cancer

On behalf of Puma Biotechnology, Inc., I respectfully request the NCCN Breast Cancer Guideline Panel review the enclosed FDA label for NERLYNX® (neratinib) + capecitabine for HER2-positive metastatic breast cancer.¹

Specific Changes: Please consider the following:

- BINV-Q1, “Other recommended regimens for HER2-Positive disease”
  - Please revise neratinib + capecitabine to a category 2A option
- BINV-Q4, “HER2-Positive Dose schedules for other recommended regimens”
  - Please revise neratinib + capecitabine to a category 2A option

FDA Clearance: neratinib is indicated:

- As a single agent, for the extended adjuvant treatment of adult patients with early-stage HER2-positive breast cancer, to follow adjuvant trastuzumab-based therapy
- In combination with capecitabine, for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting

Rationale: neratinib is an intracellular kinase inhibitor that irreversibly binds to epidermal growth factor (EGFR), HER2, and HER4.¹ Efficacy of neratinib + capecitabine in HER2-positive metastatic breast cancer has been shown in two studies that included patients who had received standard therapies including trastuzumab, T-DM1, pertuzumab, and lapatinib;²,³ additional safety results of this regimen are available from a third study.⁴ These studies demonstrate the safety and efficacy of neratinib + capecitabine as an effective option for patients with HER2-positive metastatic breast cancer.

Supporting Literature:

NALA¹,² The safety and efficacy of neratinib + capecitabine vs. lapatinib + capecitabine was studied in NALA, a randomized, multicenter, open-label clinical trial in 621 patients with metastatic HER2-positive breast cancer who had received ≥2 prior HER2-directed regimens in the metastatic setting, including trastuzumab, T-DM1, and pertuzumab (31% of patients had ≥3 regimens). Patients with asymptomatic/stable brain mets were allowed to enroll. Centrally assessed progression free survival (PFS) favored neratinib + capecitabine (HR, 0.76; 95% CI, 0.63–0.93; P=0.0059). Numerical improvements were observed in median overall survival (21.0 vs. 18.7 months; HR, 0.88; 95% CI, 0.72–1.07), objective response rate (ORR) (32.8% vs. 26.7%), duration of response (8.5 vs. 5.6 months), and cumulative incidence of CNS mets (22.8% vs. 29.2%).

²²⁰⁶³ The safety and efficacy of neratinib + capecitabine was studied in 2206, a phase 1/2 open-label, two-part trial. The phase 2 portion (part two) enrolled 72 patients with HER2-positive advanced breast cancer who had received prior trastuzumab-containing regimens; 7 received prior lapatinib. In part two, ORR was
64% in patients with no prior lapatinib and 57% in those who had prior lapatinib. Median PFS was 40.3 and 35.9 weeks, respectively. The maximum tolerated dose was determined to be neratinib 240 mg per day plus capecitabine 1,500 mg/m² (14/21 days).

Safety

Diarrhea is the main toxicity of neratinib and is common in absence of proactive management.¹ Prophylaxis was not mandated in study 2206; subsequent investigations of neratinib + capecitabine mandated loperamide during cycle 1; loperamide was used as needed after cycle 1.²,⁵ In NALA, the rate of grade ≥3 diarrhea in the neratinib arm was 24% and led to discontinuation in 2.6%; permanent discontinuation of neratinib due to any adverse reaction was 10.9% and neratinib dose reduction due to an adverse event of any grade occurred in 10%.

The following materials are submitted in support of this proposed change. We would like to acknowledge the contributions of NCCN panel members who are also co-authors on some of these publications or presentations.


Sincerely,

Deepa Lalla, B.Pharm, PhD
Head of Medical Affairs
Puma Biotechnology, Inc.